FDA: opioid antidote naloxone recalled

FDA: opioid antidote naloxone recalled
(HealthDay)—A recall of the opioid overdose antidote Naloxone was announced Monday. The U.S. Food and Drug Administration said the recall was triggered by the possibility of "loose particulate matter on the syringe plunger" that could pose a number of health risks, CNN reported.

Those risks include "local irritation, allergic reactions," and a range of cardiovascular issues, including blood clots, according to the FDA. The agency has not received any reports of patient harm from the recalled Naloxone, made by Hospira.

The recall covers single use sterile cartridge units with lot numbers 72680LL and 76510LL in 0.4 mg/mL and 1 mL in 2.5 mL strengths that were distributed to wholesalers, distributors, and hospitals in the United States, Puerto Rico, and Guam between February 2017 and February 2018, CNN reported.

Hospira said distributors and retailers should not use or distribute the recalled Naloxone and should alert stores, pharmacies, and hospitals and others who have received it.


Explore further

Overdose antidote promotes stroke recovery in rats

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA: opioid antidote naloxone recalled (2018, June 6) retrieved 25 April 2019 from https://medicalxpress.com/news/2018-06-fda-opioid-antidote-naloxone-recalled.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more